Skip to main content
SpringerLink
Log in

Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents

  • Preclinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Illudin analogs are cytotoxic to a variety of multidrug resistant cell lines, and display an unusual toxicity towards DNA helicase-deficient cell lines. Earlier illudin analogs demonstrated efficacy in several xenograft models, including a metastatic MV522 lung cancer model, resistant to conventional anticancer agents. These illudin analogs prolonged life span as compared to conventional agents, but did not induce complete remission of primary tumors. In vitro screening studies identified a semisynthetic derivative, hydroxymethylacylfulvene (HMAF, MGI-114), with increased selective cytotoxicity towards carcinoma cells. The HMAF analog was markedly effective in the experimental MV522 metastasizing lung carcinoma xenograft system, a model refractory to treatment with existing anticancer agents. Treatment with paclitaxel, doxorubicin, or cisplatin failed to significantly inhibit primary tumor growth or prolong life span of MV522 tumor-bearing animals. Treatment with mitomycin C at the LD20 increased life span in surviving animals up to 61% (p = 0.04). Treatment with HMAF induced primary tumor regression in all animals and increased life span greater than 150% (p<0.001). Thus, administration of HMAF inhibited development of lung metastasis in a model refractory to treatment with conventional anticancer agents. These results support further evaluation of HMAF as a therapeutic agent for treatment of solid tumors such as adenocarcinoma of the lung.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Garfinkel L, Silverberg E: Lung cancer and smoking trends in the United States over the past 25 years. Cancer-A Cancer J Clinicians 41:137–145, 1991

    Google Scholar 

  2. Dodds L, Davis S, Polissar L: A population-based study of lung cancer incidence trends by histological type, 1974–1981. J Natl Cancer Inst 76:21–29, 1986

    Google Scholar 

  3. Taylor CW, Crowley J, Williamson SK, Miller TP, Taylor SA, Giri TG, Stephens RL, Livingston RB: Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a South-west Oncology Group pilot study. J Clin Oncol 8:1811–1817, 1990

    Google Scholar 

  4. Ries LAG, Hankey BF, Miller BA, Hartman AM, Edwards BK: Cancer statistics reviewed 1973–1988, National Cancer Institute, NIH Publication 91-2789, Bethesda, MD, 1991

  5. Ihde DC: Chemotherapy of lung cancer. New Engl J Med 27:1434–1441, 1992

    Google Scholar 

  6. Sorenson JB, Clerici M, Hanson HH: Single-agent chemotherapy for advanced adenocarcinoma of the lung. Cancer Chemother Pharmacol 21:89–102, 1988

    Google Scholar 

  7. Sorenson JB, Hanson HH: Combination chemotherapy for advanced carcinoma of the lung. Cancer Chemother Pharmacol 21:103–116, 1988

    Google Scholar 

  8. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WI, Perry MC, Carey RW, Frei EF, Green MR: A randomized trial of induction chemotherapy plus high dose radiation versus radiation alone in stage III nonsmall-cell lung cancer. N Engl J Med 323:940–945, 1990

    CAS  PubMed  Google Scholar 

  9. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tolmey DC, Harris J, Comis R: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602–1613, 1989

    Google Scholar 

  10. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Nelson DI, Clark DC, Feld R, Arnold AN: Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer-report of a Canadian multicenter random trial. J Clin Oncol 6:633–641, 1988

    CAS  PubMed  Google Scholar 

  11. Albain KS, Crowley JJ, LeBlanc M, Livingston RB: Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9:1618–1626, 1991

    Google Scholar 

  12. Livingston RB: Treatment of advanced non-small cell lung cancer: the Southwest Oncology Group experience. Semin Oncol 15:S37-S41, 1988

    Google Scholar 

  13. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E, Tumarello D, Williams BL, Bernard JP: Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 342:19–21, 1993

    Google Scholar 

  14. Ramachandran C, Sauertegit A, Sridhar KS, Thurer RJ, Krishan A: MDR-1 gene expression, anthracycline retention, and cytotoxicity in human-tumor cells from refractory patients. Cancer Chemother Pharmacol 31:431–441, 1993

    Google Scholar 

  15. Keiner MJ, McMorris TC, Beck WT, Zamora JM, Taetle R: Preclinical evaluation of Illudins as anticancer agents. Cancer Res 47:3186–3189, 1987

    Google Scholar 

  16. Kelner MJ, McMorris TC, Taetle R: Preclinical evaluation of Illudins as anti-cancer agents. Basis for selective cytotoxicity. J Natl Cancer Inst 82:156–165, 1990

    Google Scholar 

  17. McMorris TC, Kelner MJ, Wang W, Estes LA, Montoya MM, Taetle R: Structure activity-relationships of Illudins: analogs with improved therapeutic index. J Org Chem 57:176–183, 1992

    Google Scholar 

  18. McMorris TC, Kelner MJ, Wang W, Moon S, Taetle R: On the mechanism of toxicity of Illudins. Chem Res Toxicol 3:574–579, 1990

    Google Scholar 

  19. McMorris TC, Kelner MJ, Chadha RK, Siegel JS, Moon S, Moya MM: Structure and reactivity of Illudins. Tetrahydron 45:5533–5540, 1989

    Google Scholar 

  20. Kelner MJ, McMorris TC, Taetle R: In vitro and in vivo studies on the anticancer activity of dehydroilludin M. Anticancer Res 15:873–878, 1995

    Google Scholar 

  21. Kelner MJ, McMorris TC, Estes L, Rutherford M, Montoya M, Goldstein J, Samson K, Starr R, Taetle R: Characterization of Illudin S sensitivity in DNA repair deficient Chinese hamster cells: unusually high sensitivity of ERCC2 and ERCC3 DNA helicase-deficient mutants in comparison to other chemotherapeutic agents. Biochem Pharmacol 48:403–409, 1994

    Google Scholar 

  22. Kelner MJ, McMorris TC, Estes L, Starr R, Samson K, Varki N, Taetle R: Nonresponsiveness of the metastatic human lung carcinoma MV522 xenograft to conventional anticancer agents. Anticancer Res 15:867–872, 1995

    Google Scholar 

  23. Varki NM, Roome L, Sparks RS, Miller JE: Microscopic metastases of human lung carcinoma in athymic nude mice: isolation of a metastatic variant. Int J Cancer 40:46–52, 1987

    Google Scholar 

  24. Varki NM, Tseng A, Bu TP, Estes LA: Cloned low metastatic variance from human lung carcinoma metastases. Anticancer Res 10:637–744, 1990

    Google Scholar 

  25. Collins SJ, Gallo RC, Gallagher RE: Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature 270:347–349, 1977

    Google Scholar 

  26. Leonard JE, Taetle R, To D, Rhyner K: Preclinical studies on the use of selective antibody ricin conjugated in autologous bone marrow transplantation. Blood 65:1149–1157, 1985

    Google Scholar 

  27. McMorris TC, Anchel M: Fungal metabolites. The structures of the novel sesquiterpenes illudin-A and -M. J Am Chem Soc 87:1594–1600, 1965

    Google Scholar 

  28. Anchel M, McMorris TC, Singh P: The biogenesis of illudins S and M in Clitocybe illudens. Phytochemistry 9:2339–2343, 1970

    Google Scholar 

  29. McMorris TC, Kelner MJ, Wang W, Diaz MA, Estes LA, Taetle R: Acylfulvenes, a new class of potent antitumor agents. Experientia. In press

  30. Taetle R, Rosen F, Abramson I, Benditti J, Howell S: Use of nude mouse xenografts as preclinical drug screen: in vivo activity of established chemotherapeutic agents against melanomas and ovarian carcinoma xenografts. Cancer Treat Rep 71:297–304, 1987

    Google Scholar 

  31. Altman DG: Practical Statistics for Medical Research. Chapman & Hall, New York, NY, 1991, pp 355–394

    Google Scholar 

  32. Brandsteterova E, Kelner MJ, McMorris TC, Estes L, Bagnell R, Montoya M: HPLC determination of a new anticancer agent (acylfulvene) in serum. Neoplasma 39:369–373, 1992

    Google Scholar 

  33. Brandsteterova E, Kelner MJ, McMorris TC, Wang W, Bagnell R: HPLC analysis of novel anticancer agents-Illudins and their analogs. J Liquid Chromatography 16:115–125, 1993

    Google Scholar 

  34. Kelner MJ, McMorris TC, Estes L, Starr RJ, Rutherford M, Montoya M, Samson KM, Taetle R: Efficacy of Acylfulvene Illudin analogs against a metastatic lung carcinoma MV522 nonresponsive to traditional anticancer agents. Cancer Res 55:4936–4940, 1995

    Google Scholar 

  35. Riondel J, Jacrot M, Picot F, Beriel H, Mouriquand C, Potier P: Therapeutic response to taxol of six human tumors xenografted into nude mice. Cancer Chemother Pharmacol 17:137–142, 1986

    Google Scholar 

  36. McMorris TC, Kelner MJ, Wang W, Estes LA, Montoya MA, Taetle R: Structure-activity relationships of Illudins: analogs with improved therapeutic index. J Org Chem 57:6876–6883, 1992

    Google Scholar 

  37. Sheperd FA: Treatment of advanced non-small cell lung cancer. Semin Oncol 21 (suppl 7):7–18, 1994

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, UCSD, 92103, San Diego, USA

    Michael J. Kelner, Leita Estes & Kyra M. Samson

  2. Department of Chemistry, UCSD, 92093, San Diego, USA

    Trevor C. McMorris & Wen Wnag

  3. Arizona Cancer Center, University of Arizona, 85724, Tucson, AZ, USA

    Raymond Taetle

Authors
  1. Michael J. Kelner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Trevor C. McMorris
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leita Estes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wen Wnag
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kyra M. Samson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Raymond Taetle
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kelner, M.J., McMorris, T.C., Estes, L. et al. Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents. Invest New Drugs 14, 161–167 (1996). https://doi.org/10.1007/BF00210787

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00210787

Key words

Search

Navigation